Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» non-small cell lung cancer
non-small cell lung cancer
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
Fri, 06/30/23 - 11:52 am
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn
FDA approves Biostar’s Phase II/III plans with utidelone injectable for NSCLC
Clinical Trials Arena
Fri, 06/16/23 - 09:50 am
Biostar
FDA
utidelone
UTD1
non-small cell lung cancer
This Drug Candidate Could Be a Winner for Bristol Myers
Motley Fool
Mon, 06/12/23 - 10:18 am
Bristol Myers Squibb
repotrectinib
non-small cell lung cancer
metastatic small cell lung cancer
ASCO in Review: Oncologists See Practice-Changing, Affirming Data
BioSpace
Thu, 06/8/23 - 09:26 pm
ASCO 2023
oncologists
cancer
AstraZeneca
Tagrisso
non-small cell lung cancer
Novartis
Kisqali
breast cancer
Merck
Keytruda
Moderna Therapeutics
cancer vaccine
ASCO 2023 – early first-line lung cancer data mined for datopotamab gold
EP Vantage
Wed, 06/7/23 - 10:02 am
ASCO 2023
Daiichi Sankyo
AstraZeneca
datopotamab deruxtecan
non-small cell lung cancer
ASCO 2023: AstraZeneca’s PD-1/TIGIT shows promise in checkpoint-exposed NSCLC
Clinical Trials Arena
Tue, 06/6/23 - 10:06 am
ASCO 2023
AstraZeneca
clinical trials
non-small cell lung cancer
rilvegostomig
ASCO: AstraZeneca Posts Strong Survival Data for Tagrisso in NSCLC Patients
BioSpace
Mon, 06/5/23 - 09:59 pm
ASCO 2023
AstraZeneca
Tagrisso
non-small cell lung cancer
ASCO: Gilead and Arcus's Cancer Immunotherapy Combo Faces Scrutiny Over Lower Survival Rates
BioSpace
Sun, 06/4/23 - 04:27 pm
ASCO 2023
Gilead Sciences
Arcus Biosciences
anti-TIGIT
non-small cell lung cancer
domvanalimab
ASCO: Merck bills Keytruda, used around surgery, as new standard in 'messy' early lung cancer realm
Fierce Pharma
Sun, 06/4/23 - 04:22 pm
ASCO 2023
Merck
Keytruda
non-small cell lung cancer
Yuhan makes $325M cancer bet to challenge Boehringer, Takeda
Fierce Pharma
Wed, 05/31/23 - 06:59 pm
Yuhan
cancer
Boehringer Ingelheim
Takeda
HER2 inhbitor
non-small cell lung cancer
Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023
BioSpace
Tue, 05/30/23 - 09:47 am
Hummingbird Biosciences
HMBD-002
cliincal trials
ASCO 2023
triple-negative breast cancer
non-small cell lung cancer
ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers
Fierce Pharma
Thu, 05/25/23 - 08:33 pm
ASCO 2023
Merck
Keytruda
Novartis
Kisqali
non-small cell lung cancer
early breast cancer
Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting
BioSpace
Wed, 04/19/23 - 11:21 am
Bridge Biotherapeutics
BBT-207
AACR
non-small cell lung cancer
AACR: AstraZeneca offers first look at Imfinzi's resectable lung cancer showing, fueling a key debate
Fierce Pharma
Sun, 04/16/23 - 11:22 pm
AstraZeneca
AACR
Imfinzi
non-small cell lung cancer
Pragmatica: Lung cancer trial tests streamlined design, inclusive eligibility
RAPS.org
Wed, 04/12/23 - 10:29 pm
Project Pragmatica
National Cancer Institute
non-small cell lung cancer
clinical trials
Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class
Fierce Biotech
Thu, 03/16/23 - 07:02 pm
Merck
Keytruda
clinical trials
vibostolimab
non-small cell lung cancer
metastatic non-small cell lung cancer
Despite Imfinzi fail in lung cancer trial, AZ 'encouraged' by one result: exec
Fierce Pharma
Mon, 12/19/22 - 12:29 pm
AstraZeneca
Imfinzi
lung cancer
non-small cell lung cancer
With another FDA nod, Eagle's Pemfexy gets up to speed with Lilly's Alimta
Fierce Pharma
Mon, 12/19/22 - 11:02 am
Eagle Pharmaceuticals
Pemfexy
Eli Lilly
mesothelioma
non-small cell lung cancer
Amid Buyout Buzz, Mirati Pushes Phase III NSCLC Study to Final Analysis
BioSpace
Sun, 12/4/22 - 01:17 pm
Mirati Therapeutics
clinical trials
M&A
non-small cell lung cancer
sitravantinib
Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval
Fierce Pharma
Thu, 12/1/22 - 07:11 pm
Regeneron
Libtayo
non-small cell lung cancer
Bristol Myers Squibb
Yervoy
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »